Trillions In Stimulus Going Out The Door Without Any Oversight
Laura Davison, Congressional Tax Reporter for Bloomberg, on trillions in stimulus going out unchecked, with watchdogs kept toothless by the Trump Administration. Invesco Chief Global Market Strategist...
17 Kesä 202026min
Fed Stretches Bounds In Corporate Bond Purchases: BI's Jersey
Market Drivers and earnings with Bloomberg stocks editor Dave Wilson, and Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, previews Fed Chair Jerome Powell's testimony before ...
16 Kesä 202011min
Elon Musk Takes a Gamble as Insurance Rates Skyrocket
Bloomberg's Jef Feeley, legal reporter, and Katherine Chiglinsky, insurance reporter, to discuss Tesla's new lawsuit shield against coronavirus claims. Chris Ailman, Chief Investment Officer at CalSTE...
15 Kesä 202028min
Lowering S&P Target to 3,100 By December: Stifel's Bannister
Barry Bannister, Head of Equity Strategy at Stifel, discusses why he's lowering his market forecast. Lauren Sauer, Johns Hopkins University Assistant Professor of Emergency Medicine, discusses how reo...
12 Kesä 202028min
Largest NY Hospital System Sees Return of Patients, Surgeries
Michael Dowling, President and CEO of Northwell Health, on how New York State’s largest hospital system is faring as the state begins reopening. Sarah Halzack, Bloomberg Opinion retail columnist, to d...
11 Kesä 202029min
We're Looking At A Secular Shift To Lower Rates: PGIM's Tipp
Robert Tipp, Chief Investment Strategist at PGIM, discusses fixed income markets and Fed stimulus. Jonathan Bernstein, Bloomberg Opinion politics columnist, on his column: "Be Ready for a Long Electio...
10 Kesä 202027min
Why Military Leaders Like Me Are Speaking Out: James Stavridis
Retired Navy Admiral James Stavridis, former military commander of NATO and a Bloomberg Opinion columnist, discusses his column: "Why Military Leaders Like Me Are Speaking Out." Tara Lachapelle, Bloom...
9 Kesä 202028min
Not Much Strategic Sense To An AstraZeneca-Gilead Deal
Bloomberg Opinion's Max Nisen, biotech and health care columnist, and Chris Hughes, deals columnist, on AstraZeneca mulling a bid for Gilead. Bill Smead, CEO and CIO of Smead Capital Management, on bu...
8 Kesä 202028min
